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OBJECTIVE To estimate the incidence rates of kidney-related clinical outcomes among patients with tuber-
ous sclerosis complex (TSC)-related angiomyolipoma (AML) compared to an age-matched control
cohort in the United States.
MATERIALS AND
METHODS
This was a retrospective, observational study. Administrative data from the MarketScan Re-
search Databases were used to select patients with TSC and renal AML. An age-matched group
with no TSC or renal AML was identified for comparison. Outcomes were incidence rates per
100 patient-years and number of months to development of hematuria, chronic kidney disease,
renal hemorrhage, kidney failure, and inpatient death.
RESULTS Among the commercially insured TSC-renal AML patients (N = 605) and matched controls
(N = 1815), 37.2% were <18 years old. Among Medicaid TSC-renal AML patients (N = 246)
and matched controls (N = 738), 38.6% were aged <18. In the commercial sample, in both age
groups (<18 and ≥18), the incidence rate of each clinical outcome measured was higher in the
TSC-renal AML cohort than in the control cohort, with several differences reaching statistical
significance. Compared with younger patients, older TSC-renal AML patients had higher inci-
dence rates of clinical outcomes (hematuria: 20.4 vs 8.7; chronic kidney disease: 9.6 vs 3.5; renal
hemorrhage 2.7 vs 0.7; kidney failure: 1.9 vs 0.4) and took less time on average to develop each
clinical outcome. A similar pattern of results was observed among patients with Medicaid insurance.
CONCLUSION TSC-renal AML patients are at significantly higher risk for renal morbidity relative to the general
population. UROLOGY 95: 80–87, 2016. © 2016 The Authors. Published by Elsevier Inc.
Tuberous sclerosis complex (TSC) is an autosomaldominant syndrome that arises from inactivatingmutations in either TSC1 (chromosome locus
9q34.3) or TSC2 (chromosome locus 16p13.3), which
encode hamartin and tuberin, respectively.1,2 Aberrant
expression of either protein results in benign tumor growth
in multiple organ systems, including the brain, kidneys,
heart, lungs, eyes, and skin.3 In the United States, TSC
has an estimated incidence of 1 in 6000 live births and
affects 25,000-40,000 people; worldwide, 1-2 million people
are affected by the disorder.4 TSC occurs in both chil-
dren and adults, and shows no gender, racial, or ethnic bias.5
TSC commonly affects the central nervous system and
results in an array of neuropsychiatric symptoms.6 Renal
manifestations are the second most common and poten-
tially serious presentations of TSC, with incidence rates
between 60% and 75%.7,8 An ultrasound study found that
57.5% of TSC patients between age 1 month and 59 years
had renal involvement (eg, angiomyolipomas [AMLs], renal
cysts, renal cell carcinoma), with renal cystic disease and
renal AMLs, the 2 most common phenotypic expressions
of TSC, in the kidney.2 Both of these renal pathologies cause
chronic kidney disease (CKD) and renal failure.9 In addi-
tion, kidney damage due to TSC has an early onset.10 A
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study of 41 pediatric TSC patients in Italy has seen renal
involvement (eg, AMLs, renal cysts, polycystic kidney
disease) in 36.6% of them.11
Renal AMLs develop in approximately 80% of adults
and adolescents with TSC.12,13 AMLs associated with TSC
vary in size, are typically multiple, and located bilaterally
in the kidneys.14 The presence of multiple and bilateral
lesions along with the distorted anatomy of renal AMLs
makes treatment difficult. The potential complications of
AMLs include retroperitoneal hemorrhage, hematuria, renal
bleeding, and CKD.2 AMLs can destroy the adjoining
normal renal parenchyma leading to CKD and end-stage
renal disease (ESRD).15,16 ESRD is a significant cause of
morbidity and mortality in patients with TSC.17 A survey
from 260 French dialysis centers reported that the approxi-
mate prevalence of TSC-associated ESRD was 0.7 case per
million and that of ESRD in TSC was 1 per 100.18 Simi-
larly, another survey carried out in the United Kingdom
reported an ESRD prevalence of 1% in TSC patients with
normal intellect.17 Death due to renal complications rep-
resents the second most common cause of mortality in pa-
tients with TSC and the leading cause of death in adults
with TSC.19 In a US hospital based study of TSC pa-
tients, approximately 30% (11 of 40) of deaths directly at-
tributable to TSC were due to renal complication. Of the
11 renal complication deaths reported in the study, 7 were
due to renal failure, 2 due to metastatic renal cell carci-
noma, and 2 due to bleeding AMLs.19 Current therapeu-
tic options for treating renal AMLs vary from minimally
invasive procedures such as renal arterial branch emboli-
zation, to more complex and invasive wedge resection,
partial nephrectomy, or radical nephrectomy.20
The findings from these studies demonstrate that pa-
tients with TSC-related renal AML are at high risk for de-
veloping renal complications. However, existing studies are
either based on old data or conducted in countries outside
the United States. Currently, contemporary estimates of
the real-world incidence of kidney-related clinical out-
comes in patients with TSC-related AML in the United
States are unavailable. Therefore, this retrospective study
estimates the incidence rates of kidney-related clinical out-
comes (ie, hematuria, renal hemorrhage, CKD, kidney
failure, inpatient death) among patients with TSC-
related AML in comparison to an age-matched cohort of
patients without TSC or renal AML.
MATERIALS AND METHODS
Overview of Study Design
This was a retrospective cohort study based on US administra-
tive insurance claims data for a nonprobability sample of indi-
viduals with employer-sponsored commercial health insurance or
withMedicaid-sponsored health insurance. Patients diagnosed with
TSC and renal AML and a matched cohort of patients without
TSC or renal AML were followed up until the earliest of inpa-
tient death, or the end of continuous enrollment, or the end of
the study period to measure and compare the presence of kidney-
related clinical outcomes.
Data Source
The study data were administrative insurance claims data con-
tained in the Truven Health MarketScan Commercial Claims and
Encounters (Commercial) andMulti-State Medicaid (Medicaid) da-
tabases (Truven Health Analytics, Ann Arbor, MI, US). These
databases contain enrollment information, inpatient and outpa-
tient medical, and outpatient pharmacy claims data for individu-
als with employer-sponsored primary health insurance and those
with health insurance sponsored by Medicaid programs in mul-
tiple states across the United States. The data in these data-
bases are the basis of over 700 peer-reviewed articles published
in clinical, health policy, and health economics journals cover-
ing a wide range of therapeutic areas.21-23
The study databases satisfy the conditions set forth in Sec-
tions 164.514 (a)-(b)1ii of the Health Insurance Portability and
Accountability Act of 1996 privacy rule regarding the determi-
nation and documentation of statistically de-identified data. This
study used only de-identified patient records and does not involve
the collection, use, or transmittal of individually identifiable data.
Institutional Review Board approval to conduct this study was
not necessary.
Study variables were measured from the databases using en-
rollment records, International Classification of Diseases, 9th Re-
vision, Clinical Modification (ICD-9-CM) codes, Current Procedural
Terminology 4th edition (CPT-4) codes, Healthcare Common
Procedure Coding System (HCPCS) codes, and hospital revenue
codes, as appropriate.
Patient Selection Criteria
TSC-Renal AML Cohort. The patient selection window was
January 1, 2000 to March 31, 2013 for the sample drawn from
the Commercial database and January 1, 2000 to June 30, 2012
for the sample drawn from the Medicaid database. Patients were
selected into the TSC-renal AML cohort if they met the fol-
lowing criteria: had at least 1 medical claim with a diagnosis of
TSC (ICD-9-CM 759.5) during the patient selection window;
had evidence of renal AML during the patient selection window
as determined using the following ICD-9-CM diagnosis code al-
gorithm applied to medical claims: [223.0]; or [593.81]; or [599.71
and (593.9, 789.35, or 739.36) within 30 days]; or [789.09 and
593.9 within 30 days]; or [789.09 and (789.35 or 789.36) within
30 days] and not [441.3, 441.4, 577.8, 759.0, 789.1, or 789.2].
The index date was set as the date of the first TSC or renal AML
diagnosis, whichever occurred first, during the patient selection
window.
Matched Control Cohort. To create an age- and index-year-
matched sample of patients without TSC-AML (controls), the
following steps were undertaken separately in the Commercial
and Medicaid samples. First, for each TSC-AML patient (cases),
200 potential controls who matched the case in age range during
the case’s index year were identified (age ranges: <18, 18-34, 35-
44, 45-54, 55-64, ≥65 years). Second, from each set of 200 po-
tential age-matched controls, those with any medical claims with
a diagnosis of TSC (ICD-9-CM 759.5) or any of the diagnoses
used in the renal AML algorithm during the patient selection
window were excluded. Third, 3 of the remaining potential
matches for each case were randomly selected. Finally, the index
date for each of the 3 randomly selected, age-matched, TSC, and
renal-AML-free control patients was set to the index date of the
corresponding case. The result was a group of age- and index-
year-matched control patients with no evidence of TSC or renal
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AML during the patient selection period that was matched to
the group of TSC-AML patients in the ratio of 3:1.
The study used a variable duration of follow-up, and all pa-
tients were followed from the index date until the earliest of in-
patient death, the end of continuous health plan enrollment, or
the end of the study period. There was no minimum duration of
follow-up required for inclusion in the study.
Outcome Measures
Incident clinical outcomes were measured during the variable du-
ration follow-up period. The clinical outcomes measured were he-
maturia, CKD, renal hemorrhage, kidney failure (defined as
evidence of dialysis or kidney transplant), and inpatient death.
An outcome was considered incident if it was observed during
the follow-up period, but not during all available data prior to
the index date. Due to the small sample size, no minimum base-
line period was required; therefore the amount of available data
prior to the index date was allowed to vary by patient. Evi-
dence of an incident condition was defined as at least 1 medical
claim with a diagnosis, procedure, or revenue code for the con-
dition during the follow-up period and no medical claims with
codes for the condition during all available data prior to the index
date. The codes used to define each clinical condition were avail-
able upon request. Inpatient death was identified using the re-
ported patient discharge status on inpatient claims (death outside
of the inpatient setting cannot be identified using administra-
tive claims and would have been captured instead as the end of
health plan enrollment). The risk of newly developing each of
the clinical outcomes was measured over a time period of 100
person-years (eg, a rate of 10 would signify that if we were to follow
100 people for 1 year, we would expect to observe 10 new cases
of the outcome). Incident outcome event rate was calculated as
the number of patients with outcome divided by sum of days from
index date to outcome among patients with outcome + sum of
days of follow-up among patients without outcome multiplied by
365 and 100.
Statistical Analyses
Bivariate descriptive analyses were conducted on all study out-
comes, stratified by cohort (TSC-renal AML or control). To
Table 1. Demographic characteristics (commercial population)
Age <18 y Age ≥18 y
TSC-Renal AML Control
P Value
TSC-Renal AML Control
P ValueN = 225 N = 675 N = 380 N = 1140
Age (Mean, SD) 9.8 (4.9) 11.2 (4.9) <.05 36.9 (13.0) 37.0 (14.0) .9
Age group (N, %) – –
<18 225 (100%) 675 (100%) 0 (0.0%) 0 (0.0%)
18-34 0 (0.0%) 0 (0.0%) 180 (47.4%) 540 (47.4%)
35-44 0 (0.0%) 0 (0.0%) 81 (21.3%) 243 (21.3%)
45-54 0 (0.0%) 0 (0.0%) 74 (19.5%) 222 (19.5%)
55-64 0 (0.0%) 0 (0.0%) 45 (11.8%) 135 (11.8%)
65+ 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Sex (%, N) .07 <.05
Male 102 (45.3%) 353 (52.3%) 101 (26.6%) 501 (43.9%)
Female 123 (54.7%) 322 (47.7%) 279 (73.4%) 639 (56.1%)
Months of follow-up (Mean, SD) 46.4 (35.1) 49.6 (32.4) .2 36.7 (31.2) 40.6 (30.5) <.05
Population density (N, %) <.05 <.05
Urban 186 (82.7%) 532 (78.8%) 296 (77.9%) 851 (74.6%)
Rural 30 (13.3%) 142 (21.0%) 66 (17.4%) 286 (25.1%)
Unknown 9 (4.0%) 1 (0.1%) 18 (4.7%) 3 (0.3%)
Health plan type (N, %) <.05 <.05
Comprehensive 12 (5.3%) 49 (7.3%) 21 (5.5%) 105 (9.2%)
HMO 31 (13.8%) 96 (14.2%) 48 (12.6%) 145 (12.7%)
PPO 136 (60.4%) 276 (40.9%) 242 (63.7%) 502 (44.0%)
POS 19 (8.4%) 207 (30.7%) 37 (9.7%) 330 (28.9%)
Other/Unknown 27 (12.0%) 47 (7.0%) 32 (8.4%) 58 (5.1%)
Year of index date (N, %) – –
2000 10 (4.4%) 30 (4.4%) 9 (2.4%) 27 (2.4%)
2001 6 (2.7%) 18 (2.7%) 6 (1.6%) 18 (1.6%)
2002 10 (4.4%) 30 (4.4%) 11 (2.9%) 33 (2.9%)
2003 8 (3.6%) 24 (3.6%) 20 (5.3%) 60 (5.3%)
2004 23 (10.2%) 69 (10.2%) 22 (5.8%) 66 (5.8%)
2005 9 (4.0%) 27 (4.0%) 21 (5.5%) 63 (5.5%)
2006 25 (11.1%) 75 (11.1%) 39 (10.3%) 117 (10.3%)
2007 14 (6.2%) 42 (6.2%) 31 (8.2%) 93 (8.2%)
2008 39 (17.3%) 117 (17.3%) 63 (16.6%) 189 (16.6%)
2009 27 (12.0%) 81 (12.0%) 50 (13.2%) 150 (13.2%)
2010 20 (8.9%) 60 (8.9%) 37 (9.7%) 111 (9.7%)
2011 19 (8.4%) 57 (8.4%) 39 (10.3%) 117 (10.3%)
2012 13 (5.8%) 39 (5.8%) 31 (8.2%) 93 (8.2%)
2013 2 (0.9%) 6 (0.9%) 1 (0.3%) 3 (0.3%)
AML, angiomyolipoma; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; SD, stan-
dard deviation; TSC, tuberous sclerosis complex.
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examine the outcomes for pediatric and adult populations sepa-
rately, all outcomes were additionally stratified by age on the index
date (<18 vs ≥18 years). Continuous measures were summarized
as means and standard deviations. Categorical measures were sum-
marized as counts and percentages. Statistical tests of signifi-
cance for differences in the study outcomes between patients with
and without TSC-AML were performed; chi-square tests were used
to evaluate the statistical significance of differences for categori-
cal variables. Fisher exact test was used to evaluate the statisti-
cal significance for categorical variables with rare events. To
evaluate the statistical significance of differences for normally dis-
tributed continuous variables, t tests were used. P values <.05 were
considered, a priori, to be statistically significant.
RESULTS
Study Samples
In the commercial sample, a total of 605 patients with TSC-
renal AML (cases) were matched to 1815 control pa-
tients: 37.2% (cases: N = 225; control: N = 675) were <18
years of age and 62.8% (cases: N = 380; control: N = 1140)
were ≥18 years of age. In the Medicaid sample, 246 cases
were matched to 738 controls, with 38.6% < 18, and
61.4% ≥ 18 years old.
Because more than half of the study population did not
have continuous enrollment for 6 months prior to the index
date, baseline clinical characteristics were not examined
in this study. The demographic characteristics of each of
the study cohorts are shown in Table 1. Commercially
insured TSC-renal AML patients were demographically
similar to their matched controls with 2 notable excep-
tions: first, among patients ≥18 years old, a higher propor-
tion of cases were female as compared to the controls (73%
vs 56%; P <.05). Second, among those aged <18 years, the
mean age of the controls was 1.4 years higher than that
of the cases (11.2 vs 9.8; P <.05). Among commercially
insured patients, the follow-up duration of cases was 3.2-
3.9 months shorter than that of the controls (age ≥18: 36.7
vs 40.6; age <18: 46.4 vs 49.6). The opposite pattern was
observed in Medicaid patients, with the TSC-renal AML
patients having approximately twice the duration of follow-
Table 2. Demographic characteristics (medicaid population)
Age <18 y Age ≥18 y
TSC-Renal AML Control
P Value
TSC-Renal AML Control
P ValueN = 95 N = 285 N = 151 N = 453
Age (Mean, SD) 7.7 (5.5) 8.8 (5.0) .08 36.0 (12.8) 36.1 (13.5) .9
Age group (N, %) – –
<18 95 (100%) 285 (100%) 0 (0.0%) 0 (0.0%)
18-34 0 (0.0%) 0 (0.0%) 76 (50.3%) 228 (50.3%)
35-44 0 (0.0%) 0 (0.0%) 40 (26.5%) 120 (26.5%)
45-54 0 (0.0%) 0 (0.0%) 24 (15.9%) 72 (15.9%)
55-64 0 (0.0%) 0 (0.0%) 6 (4.0%) 18 (4.0%)
65+ 0 (0.0%) 0 (0.0%) 5 (3.3%) 15 (3.3%)
Sex (%, N) .2 <.05
Male 44 (46.3%) 154 (54.0%) 61 (40.4%) 140 (30.9%)
Female 51 (53.7%) 131 (46.0%) 90 (59.6%) 313 (69.1%)
Months of follow-up (Mean, SD) 75.7 (42.8) 33.9 (26.2) <.05 73.5 (40.8) 35.4 (29.8) <.05
Population density (N, %) .2 <.05
Urban 74 (77.9%) 239 (83.9%) 113 (74.8%) 384 (84.8%)
Rural 21 (22.1%) 45 (15.8%) 36 (23.8%) 69 (15.2%)
Unknown 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Health plan type (N, %) <.05 <.05
Comprehensive 59 (62.1%) 94 (33.0%) 115 (76.2%) 270 (59.6%)
HMO 30 (31.6%) 156 (54.7%) 25 (16.6%) 150 (33.1%)
PPO 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%)
POS 6 (6.3%) 35 (12.3%) 9 (6.0%) 32 (7.1%)
Other/Unknown 0 (0.0%) 0 (0.0%) 2 (1.3%) 0 (0.0%)
Year of index date (N, %) – –
2000 15 (15.8%) 45 (15.8%) 31 (20.5%) 93 (20.5%)
2001 5 (5.3%) 15 (5.3%) 11 (7.3%) 33 (7.3%)
2002 28 (29.5%) 84 (29.5%) 40 (26.5%) 120 (26.5%)
2003 7 (7.4%) 21 (7.4%) 20 (13.2%) 60 (13.2%)
2004 6 (6.3%) 18 (6.3%) 17 (11.3%) 51 (11.3%)
2005 10 (10.5%) 30 (10.5%) 5 (3.3%) 15 (3.3%)
2006 6 (6.3%) 18 (6.3%) 3 (2.0%) 9 (2.0%)
2007 3 (3.2%) 9 (3.2%) 2 (1.3%) 6 (1.3%)
2008 4 (4.2%) 12 (4.2%) 6 (4.0%) 18 (4.0%)
2009 3 (3.2%) 9 (3.2%) 8 (5.3%) 24 (5.3%)
2010 4 (4.2%) 12 (4.2%) 7 (4.6%) 21 (4.6%)
2011 0 (0.0%) 0 (0.0%) 1 (0.7%) 3 (0.7%)
2012 4 (4.2%) 12 (4.2%) 0 (0.0%) 0 (0.0%)
2013 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Abbreviations as in Table 1.
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up as their matched controls (age ≥18 years: 73.5 vs 35.4;
age <18: 75.7 vs 33.9; Table 2).
Clinical Outcomes
Overall, the TSC-renal AML patients had higher inci-
dence rates of the studied negative clinical outcomes than
the controls (Fig. 1A,B). Among commercial patients ≥18
years old, the incidence rate per 100 patient-years was sig-
nificantly higher (P <.05) in the TSC-renal AML cohort
than in the control cohort for hematuria (20.4 vs 0.4), CKD
(9.6 vs 0.5), and kidney failure (1.9 vs 0). TSC-renal AML
patients had a higher incidence rate of inpatient death (0.4
vs 0.1), but the difference was not significant. The inci-
dence rate of renal hemorrhage was also higher for TSC-
renal AML patients (2.7 vs 0), but as no control patients
developed renal hemorrhage, confidence intervals could not
be estimated for this group, and significance inference on
renal hemorrhage could not be mathematically per-
formed. The pattern of results was the same in commer-
cially insured patients <18 years old: TSC-renal AML
patients had higher incidence rates of clinical outcomes
than controls, although the differences were statistically
significant for only hematuria and CKD. Among the TSC-
renal AML patients, hematuria had the highest inci-
dence rate, followed by CKD, renal hemorrhage, kidney
failure, and inpatient death, and the older cohort had higher
incidence rates than the younger cohort.
TSC-renal AML patients not only had higher rates of
clinical outcomes, but it took them less time to develop
such outcomes (Tables 3 and 4). Among commercially
insured patients ≥18 years of age, compared to the control
cohort, TSC-renal AML patients took much less time for
the development of hematuria (13.6 vs 47.5 months;
P <.05), CKD (15.1 vs 26.2 months; P <.05), kidney failure
(20.1 vs 57.3 months; P <.05), and inpatient death (27.8
months vs 70.4 months; P <.05). In patients <18 years of
age, the average time for the development of kidney-
related clinical outcomes did not differ significantly between
(A) Commercial Population
(B) Medicaid Population
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Figure 1. Incidence rates of clinical outcome. (Color version available online.)
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cases and controls. Finally, on average, it took younger TSC-
renal AML patients more time to develop each of the clini-
cal outcomes than their older counterparts.
Medicaid patients with TSC-renal AML also had higher
incidence rates of hematuria, CKD, renal hemorrhage, and
kidney failure than their matched controls (Fig. 1B), al-
though significant only for hematuria and CKD. Addi-
tionally, although TSC renal-AML patients in the Medicaid
cohort had nearly twice the average duration of follow-
up as patients in the commercial cohort, the incidence rates
for all clinical outcomes were nominally lower in the Med-
icaid cohort. The difference between payers was not sig-
nificant except for CKD.
DISCUSSION
This retrospective cohort study compared the real-world
incidence rates of kidney-related clinical outcomes in in-
dividuals with TSC-renal AML to those in an age-matched
control cohort. Not surprisingly, the incidence rates of he-
maturia, CKD, kidney failure, and inpatient death were sig-
nificantly higher in patients with TSC-renal AML than
in patients without TSC or renal AML, and older TSC-
renal AML patients had higher rates than their younger
counterparts. To our knowledge, other contemporary es-
timates of the rates of kidney-related clinical outcomes in
patients with TSC-renal AML in the United States are un-
available. Additionally, we know of no other studies that
Table 3. Clinical outcomes (commercial population)
Measure
Age <18 y Age ≥18 y
TSC-Renal AML Control
P Value
TSC-Renal AML Control
P ValueN = 225 N = 675 N = 380 N = 1140
Patients with hematuria (N, %) 61 (27.1%) 2 (0.3%) <.05 152 (40.0%) 13 (1.1%) <.05
Months to hematuria
(Mean, SD)
28.7 (24.8) 24.4 (25.8) .8 13.6 (17.5) 47.5 (32.2) <.05
Patients with chronic kidney
disease (N, %)
28 (12.4%) 6 (0.9%) <.05 89 (23.4%) 18 (1.6%) <.05
Months to chronic kidney
disease (Mean, SD)
32.2 (35.0) 42.1 (22.1) .5 15.1 (18.9) 26.2 (21.4) <.05
Patients with renal
hemorrhage (N, %)
6 (2.7%) 0 (0.0%) <005 28 (7.4%) 0 (0.0%) <.05
Months to renal
hemorrhage (Mean, SD)
53.4 (52.3) – – 9.4 (15.0) – –
Patients with kidney failure (N, %) 3 (1.3%) 0 (0.0%) <.05 20 (5.3%) 1 (0.1%) <.05
Months to kidney
failure (Mean, SD)
40.9 (60.7) – – 20.1 (16.6) 57.3 (–) <.05
Patients with inpatient death
(N, %)
0 (0.0%) 0 (0.0%) – 4 (1.1%) 2 (0.2%) <.05
Months to inpatient
death (Mean, SD)
– – – 27.8 (22.1) 70.4 (41.3) .2
Abbreviations as in Table 1.
Table 4. Clinical outcomes (medicaid population)
Measure
Age <18 y Age ≥18 y
TSC-Renal AML Control
P Value
TSC-Renal AML Control
P ValueN = 95 N = 285 N = 151 N = 453
Patients with hematuria (N, %) 37 (38.9%) 0 (0.0%) <.05 89 (58.9%) 6 (1.3%) <.05
Months to hematuria
(Mean, SD)
50.1 (36.3) – – 32.0 (30.2) 21.7 (21.9) .4
Patients with chronic kidney
disease (N, %)
12 (12.6%) 1 (0.4%) <.05 37 (24.5%) 21 (4.6%) <.05
Months to chronic kidney
disease (Mean, SD)
70.4 (40.1) 6.4 (–) <.05 44.6 (37.6) 29.6 (18.7) .09
Patients with renal
hemorrhage (N, %)
1 (1.1%) 0 (0.0%) .08 21 (13.9%) 0 (0.0%) <.05
Months to renal
hemorrhage (Mean, SD)
99.9 (–) – – 28.8 (29.9) – –
Patients with kidney failure (N, %) 0 (0.0%) 1 (0.4%) .3 11 (7.3%) 3 (0.7%) <.05
Months to kidney
failure (Mean, SD)
– 11.2 (–) – 42.1 (45.5) 42.5 (25.9) .9
Patients with inpatient death
(N, %)
0 (0.0%) 1 (0.4%) .3 3 (2.0%) 4 (0.9%) .3
Months to inpatient
death (Mean, SD)
– 88.7 (–) – 120.2 (5.5) 35.5 (21.8) <.05
Abbreviations as in Table 1.
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have directly compared the rates of these outcomes in TSC
renal-AML patients to those in the general population.
Preservation of renal function and prevention of renal
complications, such as potentially life-threatening hem-
orrhage, are the major goals of treating patients with TSC-
related AMLs. The guidelines recommend regular renal
imaging every 1-3 years for patients with TSC to monitor
the presence or progression of renal morbidity,24,25 al-
though the recommended modality and frequency of
imaging varies across the literature.10,26 Management of
AMLs is determined by lesion size and symptoms. Symp-
tomatic AMLs or those greater than 4-8 cm in diameter
have been typically managed via embolization, partial ne-
phrectomy, or complete nephrectomy.10,26-28 Recently, phar-
macologic management of renal AMLs with an mTOR
inhibitor has become an additional treatment option for
patients with TSC.16,26,29,30 In fact, pharmacologic therapy
has become the recommended first-line therapy for AMLs
larger than 3 cm, especially if they are growing.25 It is in-
teresting that in the commercial study population, the pro-
portion of females was much higher among those ≥18 years
than among those <18 years (73% vs 55%), whereas in
the whole commercial claims database, the proportion of
females was similar between the 2 age cohorts (52% vs
49%). This suggests a gender bias toward female in older
TSC-AML patients, which may indicate the influence of
hormonal differences in women. Future research using other
data sources on gender distribution is needed to confirm
this observation.
This study had several limitations. First, TSC, renal AML,
and clinical outcomes were identified using ICD-9-CM di-
agnosis or procedure codes, which are subject to miscoding.
Second, because more than half of the study population
would have been excluded if a 6-month baseline period of
continuous enrollment were required, clinical character-
istics were not reported for the study population. In addi-
tion, patients with incident clinical outcomes were required
to have no such clinical conditions during the baseline,
but the length of baseline varied across patients. For those
with a very short baseline period, incident clinical out-
comes may be overestimated. Third, the rate of clinical out-
comes is likely to be underestimated due to the relatively
short follow-up period. In particular, patients with com-
mercial insurance were followed for approximately 3-4 years
on average, and those with Medicaid had approximately
6 years of follow-up. Patients who may have developed the
study outcomes after the end of the follow-up period were
not captured. Fourth, death was not captured outside of
the inpatient setting (and cause of death was unknown),
so the death rate was underestimated. Fifth, the sample size
of patients with renal AML associated with TSC was very
small, thus results may have been biased by outliers. Finally,
this study was limited to only those individuals with com-
mercial health coverage or those eligible for Medicaid. Due
to the small sample size (12 patients), the Medicare popu-
lation was not reported. Consequently, results of this analy-
sis may not be generalizable to TSC-AML patients with
other insurance or without health insurance coverage.
CONCLUSION
The findings from this study indicate that patients with renal
AML associated with TSC are at a significantly higher risk
for renal morbidity relative to the general population.
Optimal treatment by nephrologists, interventional radi-
ologists, and urologists to anticipate and minimize or prevent
the complications associated with this condition is impor-
tant for long-term maintenance of renal function in pa-
tients with TSC-renal AML.
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